Prestige Consumer Healthcare Inc. — Form 8-K/A
Filed July 9, 2026 · analyzed by the 8-K Agent
8-K/A
— Neutral
significance 62/100
What the filing says
On March 19, 2026, Prestige Consumer Healthcare entered into an asset purchase agreement to acquire the OTC Wellness Business from Foundation Consumer Brands LLC (FCB), comprising brands: Breathe Right, Dimetapp, Anbesol, Alavert, Primatene, Dristan, FiberCon, Campho-Phenique, St. Joe's Low Dose Aspirin, and Bronkaid. Q1 2026 pro forma financials for the acquired business show net sales of $51.7M (vs. $50.5M prior year) and net income of $12.6M (vs. $14.8M prior year), with intangible assets and goodwill totaling $479.8M. Transaction completion date and purchase price not disclosed in this filing excerpt.
Why this rating
Meaningful acquisition expanding Prestige's OTC portfolio; acquired business ~$206M annualized revenue is ~7% of Prestige's ~$3B scale. Material but not transformational; deal structure and full economics unclear.
See more from July 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.